Abstract
Fibrin deposition occurs in health and disease. The formation of fibrin results from the sequential activation of proteases according to a scheme now well known as the coagulation cascade. A variety of stimuli can initiate this cascade and the resultant fibrin may be involved in physiological (healing) or pathological (vascular obstruction) sequelae. Resolution of fibrin deposits is accomplished by the action of an enzyme system which has as a substrate the insoluble fibrin polymers. This is the fibrinolytic system and, akin to the coagulation system, consists of sequential activation of proenzymes. Plasminogen, a circulatory ß-globulin, is converted to plasmin (fibrinolysin) by tissue or plasma kinases (activators). One of these activators, urokinase, is produced by renal cells and is excreted in the urine. The teleologically inclined will want to consider that this system maintains the urinary tract free from obstructing fibrin clots. Urokinase has been found therapeutically useful, thus stimulating a search for production sources other than human urine. One successful approach is based on cell culture, thus the inclusion of this topic in your program. I should now like to consider with you the therapeutic use of urokinase, the methods of isolation, and some recent data regarding its function.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Brogden, R.N., Speight, T.M., Avery, G.S. Streptokinase: a review of its clinical pharmacology, mechanism of action and clinical uses. Drugs 5: 357–445, 1973.
A National Cooperative Study: The Urokinase Pulmonary Embolism Trial Circulation 47: Suppl. 2: 1–108, 1973
A National Coopertive Study: The Urokinase Streptokinase Pulmonary Embolism Trial. JAMA 229: 1606–1613, 1974.
Fratantoni, J.C., Ness, P., Simon, T.L. Thrombolytic Therapy. N. Eng. J. Med. 293: 1073–1078, 1975.
Williams, J.R.B. The fibrinolytic activity of urine. Brit. J. Exp. Pathol. 32: 530–537, 1951.
Sobel, G.W., Mohled, S.R., Jones N.W., et al. Urokinase: an activator of plasma Profibrinolysin extracted from urine. Am. J. Physiol. 171; 768, 1952.
Barnett, E.V., Barone, S. An activator of plasminogen produced by cell culture. Proc. Soc. Exp. Biol. Med. 102: 308–311, 1959.
Bernik, M.B., Kwaan, H.C. Plasminogen activator activity in cultures of human tissues. J. Clin. Invest. 48: 1740–1746, 1969.
Lesuk, A., Terminiello, L., Traver, J.H. Biochemical and Biophysical Studies of Human Urokinase. Thrombosis et Diathesis Haemorrhagica 18: 293–294, 1967.
Murano, G., et al. Inhibition of high and low molecular weight urokinase by plasma inhibitors. Circulation 58:II-136, 1978.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1979 Plenum Press, New York
About this chapter
Cite this chapter
Fratantoni, J.C. (1979). Urokinase as a Cell Product. In: Petricciani, J.C., Hopps, H.E., Chapple, P.J. (eds) Cell Substrates. Advances in Experimental Medicine and Biology, vol 118. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-0997-0_14
Download citation
DOI: https://doi.org/10.1007/978-1-4684-0997-0_14
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-0999-4
Online ISBN: 978-1-4684-0997-0
eBook Packages: Springer Book Archive